A large biotech needed the correct analogs for follow-on biologics PTS in Oncology and Respiratory programs across a range of segments to assess the risk of their portfolio
Our Consultants developed rules for defining each of the relevant segments including:– “First-in-class” and “follow-on”– “Lead” and “Supplemental” indications– “Big Pharma” and “Biotech”We then conducted detailed analysis of thousands of lines of data and classified each program/indication combination for each of the relevant segmentsReferencing the assigned classifications, we used BioMedTracker’s Probability of Success Calculator to determine the average likelihood of approval for all relevant programs in Oncology and Respiratory therapy areas
The client was able to use the custom segmentation of data to risk-adjust the forecasts for several of their portfolio assets with probability of success percentages that were most suited to those assetsFree Demonstration
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: